Latest Regulatory Approval News

Kelsian Group delivered record FY26 earnings and lifted its fully franked dividend, while preparing to become a more focused bus, coach and ferry operator. The next test is execution: completing the conditional tourism sale, mobilising new contracts and delivering against FY27 EBITDA guidance.

Rand Mining lifted fiscal 2026 net profit by 82% to A$23.9 million as gold sales rose and Golden Hind delivered its first ore. The result was also helped by a A$8.7 million Raleigh impairment reversal, while higher costs, inventory and development spending reduced cash generation.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Cygnus Metals’ proposed takeover by Central Asia Metals has been pushed into October after a required Kazakhstan regulatory approval remained outstanding. The revised timetable targets scheme implementation on 27 October, but the dates remain conditional.

Saferoads Holdings Limited (ASX:SRH) returned to profit in FY2026 after product sales more than doubled, helped by $5.18 million of purchases from On-Site Rental Group. The result marks progress after the Road Safety Rentals disposal, but the next test is whether growth can continue without a repeat commitment from its largest customer.

VBX has secured $4.5 million in firm placement commitments and agreed to convert a further $2.5 million of loan notes, giving the Wuudagu bauxite project funding through its delayed feasibility study. The company has also abandoned a proposed $10 million offtake-linked facility while it tests alternative development funding options.

Orbit Resources enters FY2027 with a 17.52Mt Lewis Ponds resource, a preliminary study pointing to a A$481 million pre-tax NPV and a new polymetallic sulphide discovery outside the existing resource. The gains come with familiar junior-miner constraints: a A$3.49 million annual loss, A$3.69 million in cash and further funding still required.

Fitzroy River says conditions for its A$17.5 million Bowdens Silver royalty sale have been satisfied, with completion and receipt of funds expected within the coming week. The company plans to return most net proceeds to shareholders, although the amount, structure and timing remain undecided.

Anax Metals has reported broad, high-grade copper-equivalent intersections at Mons Cupri, including 85.90 metres at 2.89% CuEq. The results support the existing resource model and early mining sequence as Anax works towards financing, FEED completion and a potential Final Investment Decision.

Delorean Corporation and Opal have completed the concept stage for a proposed anaerobic digestion facility at Opal’s Maryvale Mill in Victoria. The project could replace natural gas used by the mill’s rotary lime kiln, but still requires further engineering, commercial work and a final investment decision.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.